

SCHERING PLOUGH CORP

Form 8-K

July 01, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

June 30, 2003

Date of Report (Date of Earliest Event Reported)

Schering-Plough Corporation

(Exact name of registrant as specified in its charter)

New Jersey
(State or other jurisdiction
of incorporation)

1-6571
(Commission File Number)

22-1918501
(IRS Employer
Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of principal executive offices, including Zip Code)

(908) 298-4000
(Registrant's telephone number, including area code)

TABLE OF CONTENTS

Item 5. Other Events and Regulation FD Disclosure

Item 7. Financial Statements and Exhibits

SIGNATURES

Exhibit Index

PRESS RELEASE

Table of Contents

Item 5. Other Events and Regulation FD Disclosure

Merck/Schering-Plough Pharmaceuticals on June 30, 2003 issued a press release titled Merck/Schering-Plough Pharmaceuticals Confirms Excellent Overall Safety Profile For ZETIA. The press release is attached to this 8-K as Exhibit 99.1.

Item 7. Financial Statements and Exhibits

(c) Exhibits. The following exhibit is filed with this 8-K:

99.1 Press Release Dated June 30, 2003, Titled Merck/Schering-Plough Pharmaceuticals Confirms Excellent Overall Safety Profile For ZETIA

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/Thomas H. Kelly

Thomas H. Kelly
Vice President and Controller

Date: July 1, 2003

Table of Contents

Exhibit Index

The following exhibits are filed with this 8-K:

99.1 Press Release Dated June 30, 2003, Titled Merck/Schering-Plough Pharmaceuticals Confirms Excellent Overall Safety Profile For ZETIA